Alembic Pharmaceuticals Q4 Results 2026 Preview, Earnings & US Business Outlook

Tue Mar 24 2026

Alembic Pharmaceuticals latest news: Alembic Pharmaceuticals Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Alembic Pharmaceuticals was listed on the National Stock Exchange (NSE) on 20-Sep-2011. Alembic Pharmaceuticals share has its face value of 2 per share, and its NSE symbol is APLLTD. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Table of Contents

Alembic Pharmaceuticals Q4 Results 2026 Preview

Alembic Pharmaceuticals Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 11-15% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 12-17% YoY.
EBITDA to rise 11-16%.
Alembic Pharmaceuticals is expected to show Moderate Growth Expected in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Alembic Pharmaceuticals Share Performance

Over the past six months, Alembic Pharmaceuticals share price has Up by 22% to 666.
Moreover, over the past year, the stock has Up by 38%
Despite this weak short-term performance, Alembic Pharmaceuticals stock has delivered a financially sound 190% return over the past 5 years.
As of today, 20-03-2026, the Alembic Pharmaceuticals share price is trading at 666 per share.

Key Factors to Watch for Alembic Pharmaceuticals Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

Visit Univest app or website to check more Alembic Pharmaceuticals latest news to make an informed investment decision.

About Alembic Pharmaceuticals

Alembic Pharmaceuticals develops and manufactures generic medicines APIs and formulations for global pharmaceutical markets.

Visit Univest app or website to check more Alembic Pharmaceuticals latest news to make an informed investment decision.

Final Thoughts

Alembic Pharmaceuticals is gear up to announce its Q4 FY26 results. Analysts expect 11-15% revenue growth, a 12-17% rise in PAT, and a 11-16% rise in EBITDA. Alembic Pharmaceuticals focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Alembic Pharmaceuticals Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.